Table 4.
Association of clinical status with rs3843549 (CASC8) in male HCC patients.
| Genotypic Frequencies | ||||
|---|---|---|---|---|
| Variable | AA (%) (n = 202) | AG + GG (%) (n = 74) | OR (95% CI) | p Value |
| Clinical Stage | ||||
| Stage I/II | 133 (65.8%) | 57 (77%) | 1.000 (reference) | |
| Stage III/IV | 69 (34.2%) | 17 (23%) | 0.575 (0.311–1.063) | p = 0.078 |
| Tumor size | ||||
| ≤T2 | 132 (65.3%) | 59 (79.7%) | 1.000 (reference) | |
| >T2 | 70 (34.7%) | 15 (20.3%) | 0.479 (0.254–0.906) | p = 0.024 * |
| Lymph node metastasis | ||||
| Negative | 194 (96%) | 72 (97.3%) | 1.000 (reference) | |
| Positive | 8 (4%) | 2 (2.7%) | 0.674 (0.14–3.247) | p = 0.622 |
| Distant metastasis | ||||
| Negative | 190 (94.1%) | 72 (97.3%) | 1.000 (reference) | |
| Positive | 12 (5.9%) | 2 (2.7%) | 0.44 (0.096–2.014) | p = 0.290 |
| Vascular invasion | ||||
| No | 167 (82.7%) | 67 (90.5%) | 1.000 (reference) | |
| Yes | 35 (17.3%) | 7 (9.5%) | 0.499 (0.211-1.178) | p = 0.112 |
| Child-Pugh grade | ||||
| A | 162 (80.2%) | 63 (85.1%) | 1.000 (reference) | |
| B or C | 40 (19.8%) | 11 (14.9%) | 0.707 (0.341–1.464) | p = 0.351 |
| HBsAg | ||||
| Negative | 102 (50.5%) | 42 (56.8%) | 1.000 (reference) | |
| Positive | 100 (49.5%) | 32 (43.2%) | 0.777 (0.455–1.329) | p = 0.357 |
| Anti-HCV | ||||
| Negative | 128 (63.4%) | 37 (50%) | 1.000 (reference) | |
| Positive | 74 (36.6%) | 37 (50%) | 1.73 (1.01–2.963) | p = 0.046 * |
| Liver cirrhosis | ||||
| Negative | 40 (19.8%) | 10 (13.5%) | 1.000 (reference) | |
| Positive | 162 (80.2%) | 64 (86.5%) | 1.58 (0.746–3.349) | p = 0.232 |
> T2: multiple tumors > 5 cm or tumor bearing a major branch of the portal or hepatic vein(s). * p value < 0.05.